Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silic… Read more
Qiagen NV (QGEN) - Net Assets
Latest net assets as of December 2025: $3.78 Billion USD
Based on the latest financial reports, Qiagen NV (QGEN) has net assets worth $3.78 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.30 Billion) and total liabilities ($2.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.78 Billion |
| % of Total Assets | 60.01% |
| Annual Growth Rate | 21.07% |
| 5-Year Change | 22.01% |
| 10-Year Change | 44.92% |
| Growth Volatility | 57.1 |
Qiagen NV - Net Assets Trend (1995–2025)
This chart illustrates how Qiagen NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Qiagen NV (1995–2025)
The table below shows the annual net assets of Qiagen NV from 1995 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.78 Billion | +5.91% |
| 2024-12-31 | $3.57 Billion | -6.31% |
| 2023-12-31 | $3.81 Billion | +9.84% |
| 2022-12-31 | $3.47 Billion | +11.95% |
| 2021-12-31 | $3.10 Billion | +10.68% |
| 2020-12-31 | $2.80 Billion | +10.30% |
| 2019-12-31 | $2.54 Billion | -3.73% |
| 2018-12-31 | $2.63 Billion | +3.70% |
| 2017-12-31 | $2.54 Billion | -2.54% |
| 2016-12-31 | $2.61 Billion | +1.76% |
| 2015-12-31 | $2.56 Billion | -3.61% |
| 2014-12-31 | $2.66 Billion | -2.42% |
| 2013-12-31 | $2.72 Billion | -0.02% |
| 2012-12-31 | $2.72 Billion | +6.51% |
| 2011-12-31 | $2.56 Billion | +3.29% |
| 2010-12-31 | $2.48 Billion | +8.08% |
| 2009-12-31 | $2.29 Billion | +57.59% |
| 2008-12-31 | $1.45 Billion | +4.43% |
| 2007-12-31 | $1.39 Billion | +145.89% |
| 2006-12-31 | $566.16 Million | +25.69% |
| 2005-12-31 | $450.46 Million | +12.51% |
| 2004-12-31 | $400.38 Million | +19.59% |
| 2003-12-31 | $334.79 Million | +27.28% |
| 2002-12-31 | $263.03 Million | +23.50% |
| 2001-12-31 | $212.97 Million | +29.41% |
| 2000-12-31 | $164.58 Million | +77.61% |
| 1999-12-31 | $92.66 Million | +26.76% |
| 1998-12-31 | $73.10 Million | +35.37% |
| 1997-12-31 | $54.00 Million | +13.21% |
| 1996-12-31 | $47.70 Million | +290.98% |
| 1995-12-31 | $12.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Qiagen NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 109835.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.75 Billion | 72.74% |
| Common Stock | $2.53 Million | 0.07% |
| Other Comprehensive Income | $-377.31 Million | -9.99% |
| Other Components | $1.40 Billion | 37.18% |
| Total Equity | $3.78 Billion | 100.00% |
Qiagen NV Competitors by Market Cap
The table below lists competitors of Qiagen NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shennan Circuits Co Ltd Class A
SHE:002916
|
$8.50 Billion |
|
Hithink RoyalFlush Info Network
SHE:300033
|
$8.50 Billion |
|
Svenska Cellulosa Aktiebolaget SCA (publ)
PINK:SVCBF
|
$8.51 Billion |
|
Subaru Corp
PINK:FUJHF
|
$8.51 Billion |
|
National Retail Properties Inc
NYSE:NNN
|
$8.46 Billion |
|
Hindustan Aeronautics Limited
NSE:HAL
|
$8.44 Billion |
|
MP Materials Corp
NYSE:MP
|
$8.43 Billion |
|
Obayashi Corporation
PINK:OBYCF
|
$8.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qiagen NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,567,339,000 to 3,778,154,000, a change of 210,815,000 (5.9%).
- Net income of 424,880,000 contributed positively to equity growth.
- Dividend payments of 54,244,000 reduced retained earnings.
- Share repurchases of 307,356,000 reduced equity.
- Other comprehensive income increased equity by 97,230,000.
- Other factors increased equity by 50,305,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $424.88 Million | +11.25% |
| Dividends Paid | $54.24 Million | -1.44% |
| Share Repurchases | $307.36 Million | -8.14% |
| Other Comprehensive Income | $97.23 Million | +2.57% |
| Other Changes | $50.30 Million | +1.33% |
| Total Change | $- | 5.91% |
Book Value vs Market Value Analysis
This analysis compares Qiagen NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 262.30x to 2.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $0.16 | $41.54 | x |
| 1996-12-31 | $0.47 | $41.54 | x |
| 1997-12-31 | $0.45 | $41.54 | x |
| 1998-12-31 | $0.52 | $41.54 | x |
| 1999-12-31 | $0.69 | $41.54 | x |
| 2000-12-31 | $1.18 | $41.54 | x |
| 2001-12-31 | $1.52 | $41.54 | x |
| 2002-12-31 | $1.87 | $41.54 | x |
| 2003-12-31 | $2.36 | $41.54 | x |
| 2004-12-31 | $2.80 | $41.54 | x |
| 2005-12-31 | $3.11 | $41.54 | x |
| 2006-12-31 | $3.83 | $41.54 | x |
| 2007-12-31 | $8.21 | $41.54 | x |
| 2008-12-31 | $7.39 | $41.54 | x |
| 2009-12-31 | $11.14 | $41.54 | x |
| 2010-12-31 | $10.69 | $41.54 | x |
| 2011-12-31 | $11.07 | $41.54 | x |
| 2012-12-31 | $11.71 | $41.54 | x |
| 2013-12-31 | $11.64 | $41.54 | x |
| 2014-12-31 | $11.11 | $41.54 | x |
| 2015-12-31 | $11.21 | $41.54 | x |
| 2016-12-31 | $11.33 | $41.54 | x |
| 2017-12-31 | $10.91 | $41.54 | x |
| 2018-12-31 | $11.29 | $41.54 | x |
| 2019-12-31 | $11.53 | $41.54 | x |
| 2020-12-31 | $12.32 | $41.54 | x |
| 2021-12-31 | $13.76 | $41.54 | x |
| 2022-12-31 | $15.53 | $41.54 | x |
| 2023-12-31 | $17.51 | $41.54 | x |
| 2024-12-31 | $16.33 | $41.54 | x |
| 2025-12-31 | $18.17 | $41.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qiagen NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.25%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.33%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.67x
- Recent ROE (11.25%) is above the historical average (9.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 19.67% | 6.49% | 1.41x | 2.15x | $1.18 Million |
| 1996 | 11.11% | 9.78% | 0.82x | 1.39x | $530.00K |
| 1997 | 16.30% | 11.84% | 0.94x | 1.46x | $3.40 Million |
| 1998 | 18.04% | 11.95% | 1.03x | 1.46x | $5.87 Million |
| 1999 | 15.03% | 9.65% | 0.97x | 1.60x | $4.65 Million |
| 2000 | 12.78% | 10.29% | 0.89x | 1.40x | $4.56 Million |
| 2001 | 16.16% | 13.05% | 0.74x | 1.68x | $13.12 Million |
| 2002 | 8.80% | 7.75% | 0.66x | 1.73x | $-3.16 Million |
| 2003 | 12.80% | 12.19% | 0.64x | 1.65x | $9.37 Million |
| 2004 | 12.16% | 12.80% | 0.53x | 1.78x | $8.67 Million |
| 2005 | 13.81% | 15.62% | 0.52x | 1.70x | $17.18 Million |
| 2006 | 12.46% | 15.14% | 0.38x | 2.14x | $13.92 Million |
| 2007 | 3.60% | 7.71% | 0.23x | 1.99x | $-89.04 Million |
| 2008 | 6.12% | 9.97% | 0.31x | 1.98x | $-56.35 Million |
| 2009 | 6.01% | 13.64% | 0.27x | 1.66x | $-91.35 Million |
| 2010 | 5.83% | 13.27% | 0.28x | 1.58x | $-103.32 Million |
| 2011 | 3.77% | 8.21% | 0.31x | 1.47x | $-158.79 Million |
| 2012 | 4.77% | 10.32% | 0.30x | 1.52x | $-141.96 Million |
| 2013 | 2.54% | 5.31% | 0.32x | 1.51x | $-202.36 Million |
| 2014 | 4.50% | 8.65% | 0.30x | 1.72x | $-142.07 Million |
| 2015 | 5.08% | 10.16% | 0.31x | 1.64x | $-125.84 Million |
| 2016 | 3.08% | 6.01% | 0.31x | 1.65x | $-180.31 Million |
| 2017 | 1.59% | 2.85% | 0.28x | 1.98x | $-213.71 Million |
| 2018 | 7.23% | 12.68% | 0.26x | 2.18x | $-73.12 Million |
| 2019 | -1.63% | -2.72% | 0.29x | 2.06x | $-295.11 Million |
| 2020 | 12.84% | 19.20% | 0.32x | 2.10x | $79.40 Million |
| 2021 | 16.55% | 22.77% | 0.37x | 1.99x | $202.94 Million |
| 2022 | 12.21% | 19.76% | 0.34x | 1.81x | $76.55 Million |
| 2023 | 8.96% | 17.37% | 0.32x | 1.61x | $-39.47 Million |
| 2024 | 2.34% | 4.23% | 0.35x | 1.59x | $-273.14 Million |
| 2025 | 11.25% | 20.33% | 0.33x | 1.67x | $47.06 Million |
Industry Comparison
This section compares Qiagen NV's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qiagen NV (QGEN) | $3.78 Billion | 19.67% | 0.67x | $8.48 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |